pharmaceuticalcommerce5d
ImmunityBio to Supply Recombinant BCG to Alleviate Tice BCG Shortage
FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.
GlobalData on MSN6d
FDA authorises ImmunityBio’s BCG alternative to treat bladder cancer
ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...
Le Lézard6d
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
ImmunityBio, Inc. , a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded access program (EAP) that will bring a vital alternative ...
Cancer Therapy Advisor5d
FDA Allows Use of Recombinant BCG Through Expanded Access Program
The FDA has authorized an expanded access program that will allow for the use of a recombinant bacillus Calmette-Guerin product.
FDA authorizes ImmunityBio to provide rBCG to urologists amid shortages
ImmunityBio (IBRX) announced the U.S. Food and Drug Administration FDA has authorized an expanded access program EAP that will bring a vital ...
Hosted on MSN6d
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies
Shares of ImmunityBio Inc. surged 16.4% on Wednesday, marking their best session in over a month, and extended gains in after ...